NCT05027568View on ClinicalTrials.gov

A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

June 28, 2021

Primary Completion Date

September 7, 2021

Study Completion Date

September 7, 2021

Conditions

Healthy

Interventions

DRUG

IOA-289

Daily oral twice daily dosing of IOA-289

DRUG

Nab paclitaxel / gemcitabine

Given in combination with IOA-289

Trial Locations (1)

37134

Centro Ricerche Cliniche di Verona srl, Verona

Sponsors

Lead Sponsor

All Listed Sponsors

lead

iOnctura

INDUSTRY

NCT05027568 - A Study to Assess an ATX Inhibitor (IOA-289) in Healthy Volunteers | Biotech Hunter | Biotech Hunter